Brief Reviews |
From the Departments of Cardiovascular Medicine (T.S., K.A., T.M., R.N.) and Clinical Bioinformatics (T.S.), Graduate School of Medicine, The University of Tokyo, Japan.
Correspondence to Toru Suzuki, MD, PhD, Department of Cardiovascular Medicine, Department of Clinical Bioinformatics, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. E-mail torusuzu-tky{at}umin.ac.jp
| Abstract |
|---|
|
|
|---|
The Krüppel-like factor (KLF) family is a recently highlighted group of zinc finger transcription factors given their important biological roles, which include the vasculature. KLF2, KLF4, KLF5, and KLF6 are notable factors that have been implicated in developmental as well as pathological vascular processes. In this brief review, we aim to provide a working view for understanding the pathological actions of KLFs in the vasculature.
Key Words: transcription gene expression zinc finger Krüppel-like factor
| Introduction |
|---|
|
|
|---|
|
|
| Eukaryotic Zinc Finger Proteins |
|---|
|
|
|---|
2 decades ago,9 is the focus of attention of the present review, but other zinc finger motifs, such as those that contain 4 cysteines (C4), are found in nuclear receptors (eg, estrogen receptor and retinoic acid receptor [RAR]) as well as GATA-type transcription factors. The cysteine and histidine residues are important to spatially coordinate and anchor the zinc atom. Comparison of the human genome with that of the yeast genome shows that transcription factors with the zinc finger motif have evolved tremendously in parallel with the increased genomic complexity.10 The selective increase of C2H2-type zinc finger transcription factors in higher eukaryotes likely reflects the need to diversify to accommodate for acquired biological functions (eg, development and differentiation). Among the C2H2-type zinc finger transcription factors are well-known cellular transcription factors such as early growth response factor-1 (Egr-1)11 and specificity protein-1 (Sp1),12 in addition to the KLFs. Therefore, the KLFs likely evolved as a subgroup of zinc finger transcription factors in response to acquired biological diversity.
| Krüppel-Like Factors |
|---|
|
|
|---|
16 members. The KLFs, when identified, were often given individual names such as EKLF (erythroid KLF), LKLF (lung KLF), etc; but at the completion of the human genome project, a letter was sent to researchers who had isolated KLFs asking for an international collaboration to unify the nomenclature by a numbering system based on chronological order of identification. Thus after, the KLFs were given numbers that are often used side by side with the original name or the numbering system alone. Hereafter, the numbered names will be used primarily in this review. Among the notable KLFs are erythroid differentiation factor KLF1 (EKLF),15 which was the first mammalian factor identified, and the tumor suppressor gene KLF6 (GBF/Zf9/COPEB), which we and others identified as a cellular factor possibly involved in HIV-1 transcription.16,17 Importantly, as will be described in detail hereafter, KLF2 (LKLF), KLF4 (GKLF/EZF), KLF5 (BTEB2/IKLF),18,19 and KLF6 (GBF/Zf9/COPEB) are of particular importance in the vasculature. KLF5 is of prominent importance as a key regulator of cardiovascular remodeling in response to stress, as shown by our murine knockout studies.20 | Vascular Roles of KLFs |
|---|
|
|
|---|
Returning to mammals, the functional role of KLF2, as shown by genetic knockout studies in mice, showed that it is important for vascular development.22 KLF2 is expressed in vascular endothelial cells (ECs) in the embryo, and null mutants show normal angiogenesis and vasculogenesis. However, null embryos die in utero because of hemorrhaging as a result of defective blood vessel morphology. That is, they show thin tunica media and aneurysmal dilatation in the veins and arteries, and aortic vascular smooth muscle cells (SMCs) are malformed (cuboidal morphology) and fail to organize into compact tunica media. EC necrosis, reduction in the number of vessel wall pericytes and differentiating SMCs, and decreased deposition of extracellular matrix are also seen. These findings suggest that ECs may regulate the assembly of the vascular tunica media and concomitant vessel wall stabilization during mammalian embryogenesis. Pathologically, KLF2 is uniquely induced by steady laminar flow in the endothelium.23 KLF2 expression has also been shown to be inhibited by the inflammatory cytokine interleukin-1ß in cultured ECs. Overexpression of KLF2 induces endothelial NO synthase expression and total enzymatic activity in addition to inhibiting the induction of vascular cell adhesion molecule-1 and endothelial adhesion molecule E-selectin in response to various proinflammatory cytokines. These data collectively implicate KLF2 as an antiatherosclerotic and anti-inflammatory regulator of endothelial activation in response to proinflammatory stimuli.24
KLF4 has also been knocked out, but a vascular phenotype has not been reported. KLF4 is highly expressed in the differentiating layers of epidermis, and null mice die shortly after birth because of loss of skin barrier function, suggesting that KLF4 is important for barrier acquisition.25 KLF4 was also isolated as a KLF expressed in the vasculature26 and is induced by shear stress.27 KLF4 has been shown to repress transforming growth factor-ß (TGF-ß)dependent increase of SMC differentiation marker genes, including
-smooth muscle actin and SM22
.28 A recent study showed that KLF4 represses myocardin-induced activation of SMC genes and expression of myocardin itself. Although KLF4 is not normally expressed in differentiated SMCs, it is upregulated by platelet-derived growth factor (PDGF)-BBtreated cultured SMCs and in response to vascular injury in vivo. Therefore, KLF4 may be a key effector of induced phenotypic switching of SMCs.29 Collectively, it is most likely that KLF4 is a pathologically induced factor in ECs as well as in vascular SMCs to regulate vascular cell function.
The role of KLF5 in the vasculature first received attention when it was isolated as a transcription factor that binds the promoter of the embryonic smooth muscle myosin heavy chain SMemb gene.30 KLF5 activates many genes inducible during cardiovascular remodeling, such as PDGF-A/B, Egr-1, plasminogen activator inhibitor-1, inducible NO synthase, and vascular endothelial growth factor receptors.31 KLF5 is abundantly expressed in embryonic SMCs and is downregulated with vascular development, but importantly, it is reinduced in proliferating neointimal SMCs in response to vascular injury. In KLF5 genetargeted mice, homozygotes die at an early embryonic stage, whereas heterozygotes are apparently normal. However, in response to external stress, the arteries of heterozygotes exhibit diminished levels of SMCs and adventitial cell activation. KLF5 activities are regulated by a variety of transcriptional regulators and nuclear receptors, such as RAR
. Interestingly, an RAR
agonist suppresses KLF5 and (cardio)vascular remodeling, whereas an RAR
antagonist activates KLF5 and induces angiogenesis. These results indicate that KLF5 is an important transcription factor in (cardio)vascular remodeling and can be a therapeutic target for (cardio)vascular disease.20
KLF6 was independently cloned by a number of groups, including ours.16,32,33 A null mutation has not been published, but its function is generally thought to reflect that of an early growth response factor induced by a variety of stimuli. At present, vascular injury induces this factor in ECs to activate its downstream genes, including TGF-ß, TGF-ß signaling receptors, and TGF-ßstimulated genes34 and urokinase plasminogen activator.35 KLF1336 and KLF1537 have also been implicated in the vasculature, but these are still early results.
To summarize, several KLFs are expressed in the vasculature and have developmental as well as pathological implications. Taking into consideration the supportive data shown by experiments in zebrafish that KLFs play a developmental role, at least a subset of KLFs most likely play an essential role in vascular development. Importantly, the KLFs play a key role in vascular pathological processes as well. A common property of the KLFs in vascular pathology is that they are induced in response to pathological stimuli (KLF2, KLF4, KLF5, KLF6). Inducibility is a distinguishing feature of vascular KLFs and is vital to understanding their functional roles and differences, as is discussed in the following section on cellular functions. Future studies using conditional vascular knockouts will likely provide a better understanding of their functional roles in the vasculature.
| Differential Cellular Effects of KLFs |
|---|
|
|
|---|
| Transcriptional Regulatory Mechanisms |
|---|
|
|
|---|
Then how do members of the KLF family exert their individual biological functions in vivo given their similar DNA binding selectivities in vitro? A possible mechanism is through differential regulation by interaction with cofactors and modifications (eg, phosphorylation, acetylation, etc), which results in additional regulation affecting the specificity of actions of KLFs. This is a recent topic of interest that we have been investigating rigorously. First, a common feature of some KLFs is interaction with the coactivator/acetylase p300 and its relative cAMP response element binding protein-binding protein (CBP). CBP and p300 also coactivate the transcriptional activity of KLF5.42,47 We have shown that p300 acetylates KLF5 and that acetylation is required for its transactivation by p300 as well as its cell growth stimulatory effects. However, of note, we have also shown that KLF6 is not acetylated by p300,48 which is an important example of the different ways of interaction among KLFs that could explain their different biological functions and responses to various stimuli.
Further, these findings led to our recent studies, which showed that an oncogenic regulator, SET, noncatalytically inhibits acetylation of KLF5 by p300 as well as inhibits KLF5-induced cell growth in addition to transactivation.42 We have also shown that a deacetylase (histone deacetylase 1 [HDAC1]) negatively regulates the transcriptional activity of KLF5 through direct interaction as well as inhibition of its interaction with p300.49 SET and HDAC1 act to negatively regulate transcription of the KLF5 downstream gene PDGF-A chain. Because p300 is induced and SET is repressed by pathological stimulus (eg, phorbol ester) and HDAC1 shows constitutive expression, a transcriptional mechanism involving positive regulation by p300 and negative regulation by SET and HDAC1 with coupled interaction and modification (acetylation) is envisioned, which would affect transcriptional regulation involving KLF5 under pathological states (Figure).
|
We have also shown that KLF5 associates with the p50 subunit of nuclear factor
B (NF-
B) in phorbol esterinduced pathologic conditions in SMCs and that this mechanism is responsible for the delayed yet persistent activation of PDGF-A chain by KLF5 after the initial activation by Egr-1 as mediated by a novel specific interaction with the inducible p50 NF-
B subunit.31 These observations collectively suggest that differential use of cofactors according to different conditions is an important manner in which the functions of KLFs are modulated. This is indeed rational because zinc finger transcription factors often are regulated by proteinprotein interaction by associating among themselves as homodimers or heterodimers as well as other cofactors through the zinc finger domain.50 Given these findings, it is tempting to assume that proteinprotein interaction as well as modification by cofactors play an important role in regulating the KLFs in pathological states. Comprehensive analysis showing differential use of interacting proteins or modifications will add to our understanding of how the actions of KLFs are modulated.
Finally, a point of interest to note is that the KLFs and the relative Sp1 have in common the property to interact with chromatin-associated factors. In fact, the Sp/KLFs, aside from histones, are the only family of DNA-binding factors known to interact with all 3 types of chromatin-remodeling factors, including chemical modification enzymes (eg, acetylases and deacetylases) as well as ATP-independent (eg, histone chaperones) and ATP-dependent (eg, Swi/Snf) nucleosome-remodeling enzymes.8,42,51,52 Therefore, it is tempting to envision given that the zinc finger transcription factors are the most widely evolved family of transcription factors in eukaryotes, biological diversification coupled with the emergence of chromatin was a necessary process to further allow for efficient use and access to the tightly packaged DNA genetic information. Elucidating the regulatory pathway involving chromatin-associated factors may be the key to understanding the biological role and regulation of KLFs as well as for other transcription factors.52
| Perspective |
|---|
|
|
|---|
| Acknowledgments |
|---|
Received January 31, 2005; accepted March 30, 2005.
| References |
|---|
|
|
|---|
2. Turner J, Crossley M. Mammalian Kruppel-like transcription factors: more than just a pretty finger. Trends Biochem Sci. 1999; 24: 236240.[CrossRef][Medline] [Order article via Infotrieve]
3. Dang DT, Pevsner J, Yang VW. The biology of the mammalian Kruppel-like family of transcription factors. Int J Biochem Cell Biol. 2000; 32: 11031121.[CrossRef][Medline] [Order article via Infotrieve]
4. Bieker JJ. Kruppel-like factors: three fingers in many pies. J Biol Chem. 2001; 276: 3435534358.
5. Black AR, Black JD, Azizkhan-Clifford J. Sp1 and Kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol. 2001; 188: 143160.[CrossRef][Medline] [Order article via Infotrieve]
6. Bouwman P, Philipsen S. Regulation of the activity of Sp1-related transcription factors. Mol Cell Endocrinol. 2002; 195: 2738.[CrossRef][Medline] [Order article via Infotrieve]
7. Kaczynski J, Cook T, Urrutia R. Sp1- and Kruppel-like transcription factors. Genome Biol. 2003; 4: 206.[CrossRef][Medline] [Order article via Infotrieve]
8. Suzuki T, Horikoshi M, Nagai R. Regulation of the Sp/KLF-family of transcription factors: focus on post-transcriptional modification and protein-protein interaction in the context of chromatin. Gene Ther Mol Biol. 2003; 7: 9197.
9. Diakun GP, Fairall L, Klug A. EXAFS study of the zinc-binding sites in the protein transcription factor IIIA. Nature. 1986; 324: 698699.[CrossRef][Medline] [Order article via Infotrieve]
10. Tupler R, Perini G, Green MR. Expressing the human genome. Nature. 2001; 409: 832833.[CrossRef][Medline] [Order article via Infotrieve]
11. Sukhatme VP, Cao XM, Chang LC, Tsai-Morris CH, Stamenkovich D, Ferreira PC, Cohen DR, Edwards SA, Shows TB, Curran T, et al. A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization. Cell. 1988; 53: 3743.[CrossRef][Medline] [Order article via Infotrieve]
12. Dynan WS, Tjian R. The promoter-specific transcription factor Sp1 binds to upstream sequences in the SV40 early promoter. Cell. 1983; 35: 7987.[CrossRef][Medline] [Order article via Infotrieve]
13. Preiss A, Rosenberg UB, Kienlin A, Seifert E, Jackle H. Molecular genetics of Kruppel, a gene required for segmentation of the Drosophila embryo. Nature. 1985; 313: 2732.[CrossRef][Medline] [Order article via Infotrieve]
14. Ruppert JM, Kinzler KW, Wong AJ, Bigner SH, Kao FT, Law ML, Seuanez HN, OBrien SJ, Vogelstein B. The GLI-Kruppel family of human genes. Mol Cell Biol. 1988; 8: 31043113.
15. Miller IJ, Bieker JJ. A novel, erythroid cell-specific murine transcription factor that binds to the CACCC element and is related to the Kruppel family of nuclear proteins. Mol Cell Biol. 1993; 13: 27762786.
16. Suzuki T, Yamamoto T, Kurabayashi M, Nagai R, Yazaki Y, Horikoshi M. Isolation and initial characterization of GBF, a novel DNA-binding zinc finger protein that binds to the GC-rich binding sites of the HIV-1 promoter. J Biochem (Tokyo). 1998; 124: 389395.
17. Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, Glucksman MJ, Narla J, Eng FJ, Chan AM, Ferrari AC, Martignetti JA, Friedman SL. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science. 2001; 294: 25632566.
18. Sogawa K, Imataka H, Yamasaki Y, Kusume H, Abe H, Fujii-Kuriyama Y. cDNA cloning and transcriptional properties of a novel GC box-binding protein, BTEB2. Nucleic Acids Res. 1993; 21: 15271532.
19. Shi H, Zhang Z, Wang X, Liu S, Teng CT. Isolation and characterization of a gene encoding human Kruppel-like factor 5 (IKLF): binding to the CAAT/GT box of the mouse lactoferrin gene promoter. Nucleic Acids Res. 1999; 27: 48074815.
20. Shindo T, Manabe I, Fukushima Y, Tobe K, Aizawa K, Miyamoto S, Kawai-Kowase K, Moriyama N, Imai Y, Kawakami H, Nishimatsu H, Ishikawa T, Suzuki T, Morita H, Maemura K, Sata M, Hirata Y, Komukai M, Kagechika H, Kadowaki T, Kurabayashi M, Nagai R. Kruppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat Med. 2002; 8: 856863.[Medline] [Order article via Infotrieve]
21. Oates AC, Pratt SJ, Vail B, Yan Y, Ho RK, Johnson SL, Postlethwait JH, Zon LI. The zebrafish klf gene family. Blood. 2001; 98: 17921801.
22. Kuo CT, Veselits ML, Barton KP, Lu MM, Clendenin C, Leiden JM. The LKLF transcription factor is required for normal tunica media formation and blood vessel stabilization during murine embryogenesis. Genes Dev. 1997; 11: 29963006.
23. Dekker RJ, van Soest S, Fontijn RD, Salamanca S, de Groot PG, VanBavel E, Pannekoek H, Horrevoets AJ. Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Kruppel-like factor (KLF2). Blood. 2002; 100: 16891698.
24. SenBanerjee S, Lin Z, Atkins GB, Greif DM, Rao RM, Kumar A, Feinberg MW, Chen Z, Simon DI, Luscinskas FW, Michel TM, Gimbrone MA Jr, Garcia-Cardena G, Jain MK. KLF2 is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med. 2004; 199: 13051315.
25. Segre JA, Bauer C, Fuchs E. Klf4 is a transcription factor required for establishing the barrier function of the skin. Nat Genet. 1999; 22: 356360.[CrossRef][Medline] [Order article via Infotrieve]
26. Yet SF, McANulty MM, Folta SC, Yen HW, Yoshizumi M, Hsieh CM, Layne MD, Chin MT, Wang H, Perrella MA, Jain MK, Lee ME. Human EZF, a Kruppel-like zinc finger protein, is expressed in vascular endothelial cells and contains transcriptional activation and repression domains. J Biol Chem. 1998; 273: 10261031.
27. McCormick SM, Eskin SG, McIntire LV, Teng CL, Lu CM, Russell CG, Chittur KK. DNA microarray reveals changes in gene expression of shear stressed human umbilical vein endothelial cells. Proc Natl Acad Sci U S A. 2001; 98: 89558960.
28. Adam PJ, Regan CP, Hautmann MB, Owens GK. Positive- and negative-acting Kruppel-like transcription factors bind a transforming growth factor beta control element required for expression of the smooth muscle cell differentiation marker SM22alpha in vivo. J Biol Chem. 2000; 275: 3779837806.
29. Liu Y, Sinha S, McDonald OG, Shang Y, Hoofnagle MH, Owens GK. Kruppel-like factor 4 abrogates myocardin-induced activation of smooth muscle gene expression. J Biol Chem. 2004.
30. Watanabe N, Kurabayashi M, Shimomura Y, Kawai-Kowase K, Hoshino Y, Manabe I, Watanabe M, Aikawa M, Kuro-o M, Suzuki T, Yazaki Y, Nagai R. BTEB2, a Kruppel-like transcription factor, regulates expression of the SMemb/Nonmuscle myosin heavy chain B (SMemb/NMHC-B) gene. Circ Res. 1999; 85: 182191.
31. Aizawa K, Suzuki T, Kada N, Ishihara A, Kawai-Kowase K, Matsumura T, Sasaki K, Munemasa Y, Manabe I, Kurabayashi M, Collins T, Nagai R. Regulation of platelet-derived growth factor-A chain by Kruppel-like factor 5: new pathway of cooperative activation with nuclear factor-
B. J Biol Chem. 2004; 279: 7076.
32. Ratziu V, Lalazar A, Wong L, Dang Q, Collins C, Shaulian E, Jensen S, Friedman SL. Zf9, a Kruppel-like transcription factor up-regulated in vivo during early hepatic fibrosis. Proc Natl Acad Sci U S A. 1998; 95: 95009505.
33. Koritschoner NP, Bocco JL, Panzetta-Dutari GM, Dumur CI, Flury A, Patrito LC. A novel human zinc finger protein that interacts with the core promoter element of a TATA box-less gene. J Biol Chem. 1997; 272: 95739580.
34. Botella LM, Sanchez-Elsner T, Sanz-Rodriguez F, Kojima S, Shimada J, Guerrero-Esteo M, Cooreman MP, Ratziu V, Langa C, Vary CP, Ramirez JR, Friedman S, Bernabeu C. Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood. 2002; 100: 40014010.
35. Kojima S, Hayashi S, Shimokado K, Suzuki Y, Shimada J, Crippa MP, Friedman SL. Transcriptional activation of urokinase by the Kruppel-like factor Zf9/COPEB activates latent TGF-beta1 in vascular endothelial cells. Blood. 2000; 95: 13091316.
36. Martin KM, Metcalfe JC, Kemp PR. Expression of Klf9 and Klf13 in mouse development. Mech Dev. 2001; 103: 149151.[CrossRef][Medline] [Order article via Infotrieve]
37. Gray S, Feinberg MW, Hull S, Kuo CT, Watanabe M, Sen-Banerjee S, DePina A, Haspel R, Jain MK. The Kruppel-like factor KLF15 regulates the insulin-sensitive glucose transporter GLUT4. J Biol Chem. 2002; 277: 3432234328.
38. Shields JM, Christy RJ, Yang VW. Identification and characterization of a gene encoding a gut-enriched Kruppel-like factor expressed during growth arrest. J Biol Chem. 1996; 271: 2000920017.
39. Ton-That H, Kaestner KH, Shields JM, Mahatanankoon CS, Yang VW. Expression of the gut-enriched Kruppel-like factor gene during development and intestinal tumorigenesis. FEBS Lett. 1997; 419: 239243.[CrossRef][Medline] [Order article via Infotrieve]
40. Benzeno S, Narla G, Allina J, Cheng GZ, Reeves HL, Banck MS, Odin JA, Diehl JA, Germain D, Friedman SL. Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res. 2004; 64: 38853891.
41. Sun R, Chen X, Yang VW. Intestinal-enriched Kruppel-like factor (Kruppel-like factor 5) is a positive regulator of cellular proliferation. J Biol Chem. 2001; 276: 68976900.
42. Miyamoto S, Suzuki T, Muto S, Aizawa K, Kimura A, Mizuno Y, Nagino T, Imai Y, Adachi N, Horikoshi M, Nagai R. Positive and negative regulation of the cardiovascular transcription factor KLF5 by p300 and the oncogenic regulator SET through interaction and acetylation on the DNA-binding domain. Mol Cell Biol. 2003; 23: 85288541.
43. Rozenblum E, Vahteristo P, Sandberg T, Bergthorsson JT, Syrjakoski K, Weaver D, Haraldsson K, Johannsdottir HK, Vehmanen P, Nigam S, Golberger N, Robbins C, Pak E, Dutra A, Gillander E, Stephan DA, Bailey-Wilson J, Juo SH, Kainu T, Arason A, Barkardottir RB, Nevanlinna H, Borg A, Kallioniemi OP. A genomic map of a 6-Mb region at 13q21q22 implicated in cancer development: identification and characterization of candidate genes. Hum Genet. 2002; 110: 111121.[CrossRef][Medline] [Order article via Infotrieve]
44. Klevit RE. Recognition of DNA by Cys2,His2 zinc fingers. Science. 1991; 253: 1367, 1393.
45. Suzuki M, Gerstein M, Yagi N. Stereochemical basis of DNA recognition by Zn fingers. Nucleic Acids Res. 1994; 22: 33973405.
46. Gillemans N, Tewari R, Lindeboom F, Rottier R, de Wit T, Wijgerde M, Grosveld F, Philipsen S. Altered DNA-binding specificity mutants of EKLF and Sp1 show that EKLF is an activator of the beta-globin locus control region in vivo. Genes Dev. 1998; 12: 28632873.
47. Zhang Z, Teng CT. Phosphorylation of Kruppel-like factor 5 (KLF5/IKLF) at the CBP interaction region enhances its transactivation function. Nucleic Acids Res. 2003; 31: 21962208.
48. Suzuki T, Kimura A, Nagai R, Horikoshi M. Regulation of interaction of the acetyltransferase region of p300 and the DNA-binding domain of Sp1 on and through DNA binding. Genes Cells. 2000; 5: 2941.[Abstract]
49. Matsumura T, Suzuki T, Aizawa K, Munemasa Y, Muto S, Horikoshi M, Nagai R. The deacetylase HDAC1 negatively regulates the cardiovascular transcription factor Kruppel-like factor 5 through direct interaction. J Biol Chem. 2005; 280: 1212312129.
50. Mackay JP, Crossley M. Zinc fingers are sticking together. Trends Biochem Sci. 1998; 23: 14.[CrossRef][Medline] [Order article via Infotrieve]
51. Suzuki T, Muto S, Miyamoto S, Aizawa K, Horikoshi M, Nagai R. Functional interaction of the DNA-binding transcription factor Sp1 through its DNA-binding domain with the histone chaperone TAF-I. J Biol Chem. 2003; 278: 2875828764.
52. Suzuki T, Nagai R, Yazaki Y. Mechanisms of transcriptional regulation of gene expression in smooth muscle cells. Circ Res. 1998; 82: 12381242.
This article has been cited by other articles:
![]() |
M. V. Autieri Kruppel-Like Factor 4: Transcriptional Regulator of Proliferation, or Inflammation, or Differentiation, or All Three? Circ. Res., June 20, 2008; 102(12): 1455 - 1457. [Full Text] [PDF] |
||||
![]() |
T. T. Tuomisto, H. Lumivuori, E. Kansanen, S.-K. Hakkinen, M. P. Turunen, J. V. van Thienen, A. J. Horrevoets, A.-L. Levonen, and S. Yla-Herttuala Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2 Cardiovasc Res, April 1, 2008; 78(1): 175 - 184. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Woo, T. Shishido, C. McClain, J. H. Lim, J.-D. Li, J. Yang, C. Yan, and J.-i. Abe Extracellular Signal-Regulated Kinase 5 SUMOylation Antagonizes Shear Stress-Induced Antiinflammatory Response and Endothelial Nitric Oxide Synthase Expression in Endothelial Cells Circ. Res., March 14, 2008; 102(5): 538 - 545. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Munemasa, T. Suzuki, K. Aizawa, S. Miyamoto, Y. Imai, T. Matsumura, M. Horikoshi, and R. Nagai Promoter Region-Specific Histone Incorporation by the Novel Histone Chaperone ANP32B and DNA-Binding Factor KLF5 Mol. Cell. Biol., February 1, 2008; 28(3): 1171 - 1181. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Cheli, D. Jensen, P. Marchese, D. Habart, T. Wiltshire, M. Cooke, J. A. Fernandez, J. Ware, Z. M. Ruggeri, and T. J. Kunicki The Modifier of hemostasis (Mh) locus on chromosome 4 controls in vivo hemostasis of Gp6-/- mice Blood, February 1, 2008; 111(3): 1266 - 1273. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Rao, L. Yang, G. Garcia-Cardena, and F. W. Luscinskas Endothelial-Dependent Mechanisms of Leukocyte Recruitment to the Vascular Wall Circ. Res., August 3, 2007; 101(3): 234 - 247. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. B. Atkins and M. K. Jain Role of Kruppel-Like Transcription Factors in Endothelial Biology Circ. Res., June 22, 2007; 100(12): 1686 - 1695. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Suzuki, T. Nishi, T. Nagino, K. Sasaki, K. Aizawa, N. Kada, D. Sawaki, Y. Munemasa, T. Matsumura, S. Muto, et al. Functional Interaction between the Transcription Factor Kruppel-like Factor 5 and Poly(ADP-ribose) Polymerase-1 in Cardiovascular Apoptosis J. Biol. Chem., March 30, 2007; 282(13): 9895 - 9901. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Thum and J. Bauersachs Sports or statins for atheroprotection? New insight from Kruppel-like factor 2 Cardiovasc Res, November 1, 2006; 72(2): 193 - 195. [Full Text] [PDF] |
||||
![]() |
W. Ruf Flow perturbation is linked to endothelial par signaling. Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 962 - 964. [Full Text] [PDF] |
||||
![]() |
J.E. Ferguson III, R. W. Kelley, and C. Patterson Mechanisms of Endothelial Differentiation in Embryonic Vasculogenesis Arterioscler. Thromb. Vasc. Biol., November 1, 2005; 25(11): 2246 - 2254. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |